Phase 2
Completed N=30
Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)
Source: ClinicalTrials.gov NCT03611153 ↗Enrolled (actual)
30
Serious AEs
3.3%
Results posted
Jan 2025
Primary outcomePrimary: Change in Exercise Pulmonary Capillary Wedge Pressure (PCWP) — -1; -4 mmHg — p=0.040
Summary
Researchers are studying the effect of a single dose of oral myeloperoxidase on heart failure versus placebo.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Exercise Pulmonary Capillary Wedge Pressure (PCWP) |
-1; -4 | 0.040 sig |
| PRIMARY Exercise Pulmonary Capillary Wedge Pressure (PCWP) |
31; 32 | — |
| SECONDARY Change in Resting Pulmonary Capillary Wedge Pressure (PCWP) |
-2; -2 | 0.777 |
| SECONDARY Change in Exercise Central Pressures |
0; 0; -2; -4; -1; -4 | 0.805 |
| SECONDARY Change in Resting Central Pressures |
0; 0; -3; -3; -1; -2 | 0.786 |
| SECONDARY Change in Exercise Transmyocardial Lactate Ratio |
0.05; -0.01 | 0.418 |
| SECONDARY Change in Resting Transmyocardial Lactate Ratio |
0.16; 0.10 | 0.669 |
Eligibility Criteria
Inclusion Criteria
- Males and females of non-childbearing potential
- Age ≥ 30 years
- Symptoms of dyspnea (II-IV) at the time of screening
- Ejection Fraction (EF) ≥ 50% as determined on imaging study within 12 months of enrollment
- Catheterization documented elevated filling pressures at rest (PCWP ≥15) or with exercise (PCWP ≥25)
Exclusion Criteria
- Use of nitrates, phosphodiesterase 5 inhibitors or other NO-providing therapy in the past 24 hours of screening
- Significant valvular disease (>moderate left-sided regurgitation, >mild stenosis)
- Requirement of intravenous heparin at the start of case
- Severe pulmonary parenchymal disease
- Acute coronary syndrome or coronary disease requiring revascularization in the judgement of investigators
- Resting systolic blood pressure < 100 mmHg
- Constrictive pericarditis
- Infiltrative, restrictive, or hypertrophic obstructive cardiomyopathies
- Previous anaphylaxis to any drug
- Pregnancy or breastfeeding mothers
- High Output heart failure
- Active thyroid disease
- Treatment with a new chemical entity (defined as a compound which has not been approved for marketing) within the preceding 3 months
- Patients with any prior allergy to propylthiouracil
Data sourced from ClinicalTrials.gov (NCT03611153). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.